archive-org.com » ORG » M » MATWIN.ORG

Total: 320

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • MATWIN, Maturation & accelerating translation with industry
    organise les 30 juin et 1er juillet 2016 son Lire Abonnez vous Vous ne possédez pas la bonne version du plugin Adobe Flash MEET2WIN 2ème édition 12 et 13 mai 2016 Bordeaux MATWIN organisera les 12 et 13 mai 2016 à Bordeaux la 2 ème édition de MEET2WIN convention d affaires française entièrement dédiée à l open innovation à la recherche collaborative et au transfert de technologies Programme inscriptions et

    Original URL path: http://www.matwin.org/ (2016-02-11)
    Open archived version from archive


  • MATWIN, Maturation & accelerating translation with industry
    PACA annual congress June 30th July 1st 2016 The Cancéropôle PACA is organizing on June 30th and July 1st 2016 Read more Subscribe to You do not have the correct version of the plugin Adobe Flash MEET2WIN 2nd edition Bordeaux 2016 May 12th 13th MATWIN will be organizing in Bordeaux next May 12 th and 13 th 2016 the 2 nd edition of MEET2WIN French Business Convention entirely dedicated to

    Original URL path: http://www.matwin.org/?lg=en (2016-02-11)
    Open archived version from archive

  • MATWIN Presentation
    projects in oncology up to the pre clinical proof of concept The programme identifies world class projects to accelerate their transfer from bench to the bedside MATWIN thus helps promoting French research by furthering innovation and early public private partnerships History In 2009 the Cancéropôle Grand Sud Ouest and its industrial committee started a programme meaning to improve technology transfer MATWIN Maturation and Accelerating Translation With Industry After experimentations in 2009 in the southwest of France the programme progressively opened to other Cancéropoles The creation of MATWIN as an independant company SAS gave to the programme a nationwide dimension Since June 29 th 2015 UNICANCER group gathering the 20 French Comprehensive Cancer Centers has become MATWIN sole owner MATWIN is supported by twelve of the world s largest pharmaceutical companies Amgen AstraZeneca Bayer HealthCare Bristol Myers Squibb Celgene GlaxoSmithKline Janssen Novartis Pfizer Pierre Fabre Roche Sanofi and by the French Cancéropôles network Download MATWIN missions This unique platform at this early research stage supports the development of translational research thanks to a collaborative process with oncology research teams and pharmaceuticals companies MATWIN identifies and selects world class oncology research projects increases their industrial attractiveness optimizes their transfer potential to the

    Original URL path: http://www.matwin.org/matwin/presentation-p4.html (2016-02-11)
    Open archived version from archive

  • Commitees
    the Faculty of Biology and Medicine January 2011 He has been actively involved in pre clinical and translational research in tumor immunology and immunotherapy His main interests focus on the study of tumor antigens human T cell responses and development of immunotherapy of cancer Dr Romero has co authored over 250 publications in peer reviewed journals and serves as editor in various biomedical journals including Editor in Chief of the Journal for Immunotherapy of Cancer Industrial Board Members Marianne ASHFORD is Principal Scientist at AstraZeneca Her current work is focussed primarily on looking at novel drug delivery approaches to improve the therapeutic index of drugs and enable new targets in Oncology She is a member of the AstraZeneca Oncology Innovative Medicines Science Leadership Team which is responsible for the early Oncology portfolio She has over 20 years experiences within the Pharmaceutical Industry in line project management and scientific leadership roles and she has experience of all stages of the drug discovery and development process Mike BURGESS joined Bristol Myers Squibb in January of 2013 as Senior Vice President Exploratory Clinical and Translational Research Before joining Bristol Myers Squibb Dr Burgess was interim head of Hoffman La Roche s Pharma Research and Early Development organization Prior to that he led the Hoffman La Roche Oncology Discovery and Translational Area one of five disease focused organizations At the same time served as head of Global Large Molecule Research with responsibility for antibody engineering and early production Before joining Hoffman La Roche Dr Burgess was at Eli Lilly and Company as a Medical Fellow Dr Burgess is a trained pediatric oncologist and was a Cancer Research Campaign Clinical Fellow He received his medical training and Ph D from the University of Bristol U K and is a member of the Royal College of Physicians and of the Royal College of Pediatrics and Child Health Laurent DEBUSSCHE obtained his PhD in biological chemistry at Université Pierre et Marie Curie and Institut National Agronomique Paris Grignon His work on Vitamin B12 biosynthesis pathway eluciadtion was recognized by Doisteau Blustet French National Academy of Sciences in 1992 Located in Vitry Research site he has close to 30 years experience in pharmaceutical industry Since 1987 he has been involved in several research projects in oncology He is Research Director at Sanofi joined the management team of Oncology Research Department in 1998 has an extensive experience in industrial and academic project direction at national and international level as well as in external opportunity evaluation He contributed to entry in clinical development of several chemical and biological entities He is co author of more than 60 scientific publications He is currently leading the Sanofi Oncology Research Department in Vitry Patrice DENÈFLE Ph D HDR and Associate Professor at Paris Descartes has pioneered the field of gene therapy and has initiated multiple programs in Human genetics functional genomics and Onco pharmacogenomics at Rhône Poulenc Rorer then Sanofi Aventis After 3 years as CSO and head of translational R D at

    Original URL path: http://www.matwin.org/acteurs/instances-p14.html (2016-02-11)
    Open archived version from archive

  • Programme process
    the engineer school ESBS He is a member of the scientific advisory board of iTeos Therapeutics and Centre de Recherche des Cordeliers He is also member of the investment committee of the TTO SATT Conectus Before Anagenesis Biotechnologies he co founded Transgene Spin off ElsaLys Biotech He was for 8 years VP R D of Transgene SA From 2002 to 2005 he launched and managed the Canceropole Lyon Rhône Alpes From 1992 to 2002 he headed the Centre d immunologie Pierre Fabre From 1998 to 2002 he was Director of the Immunology Department of the Glaxo Wellcome Institute in Switzerland From 1985 to 1987 he was scientist at the Research Centre of Schering Plough in France He is author and co author of more than 200 publications and reviews H index 55 30 13 Jean Yves holds a PhD in Immunology a Thèse 3ème cycle in Biochemistry and followed the Senior Management Program of the London Business School in the UK Christian Cailliot is the research director at the Unicancer organization and as such manages the R D departmentand He s also the marketing director of CTRS a French laboraty focused on orphan diseases Denis Carniato is the founder and president of DC2A Consulting a consulting company specialized in scientific and operational support for drug discovery and medicinal chemistry He participates in the evaluation and project maturation for public and private structures in several therapeutic areas such as oncology infectious and viral diseases diabetes and bone diseases After a PhD in organic chemistry from the university Pierre Marie Curie and a postdoctoral fellow at Hoechst AG in Frankfurt he worked for 25 years in drug discovery in large pharmaceutical companies Roussel Uclaf HMR Théramex Merck Serono then as VP chemistry at Cytomics Pharmaceuticals a biotechnology company specialized in oncology During his career Denis Carniato intervened in twenty research projects three of which reached the clinical phases He is the author of over 40 publications and patents and received the approval of the French research tax credit for 2015 2019 years Bernard Deschamp is currently CEO and co founder of CTRS laboratories created in 2002 and specialized in orphan drugs and cell therapy After a basic training of biologist he joined the pharmaceutical industry in 1975 firstly working for Warner Lambert Substantia Parke Davis then Squibb and BMS after the merger and following a special one year mission for Novartis then he joined Amgen where he contribute at the creation of Amgen France His cursus has been done specially in marketing operations and general management in France and Europe organizations He had the opportunity to complete his initial scientific background by a whole training in business and management ESSEC HEC INSEAD Dr Herrera has more than 25 years of experience in the pharmaceutical industry with a strong focus in oncology drug development and marketing Before setting up his own oncology consultancy Alain Oncologie Consulting AOC he headed the global Oncology business at Sanofi for ten years where he was Vice President

    Original URL path: http://www.matwin.org/programme/le_process-p16.html (2016-02-11)
    Open archived version from archive

  • MEET2WIN 2016
    2016 the 2 nd edition of its Business Convention entirely dedicated to open innovation collaborative research and technology transfer As suggested by the 1st edition participants MATWIN has chosen to organize the MEET2WIN business convention in a one and a half day this year in order to maximize face to face meetings possibilities Organized around one to one meetings and bringing together all the parties involved in oncology innovation MEET2WIN will offer the opportunity to meet representatives of big pharma companies biotechs start up project leaders researchers clinicians TTO s investors etc to increase R D private public partnerships Subject area oncology prevention diagnosis treatment etc MEET2WIN will be a one and a half day business convention combining conferences flash project presentations one to one prescheduled business meetings as well as exhibition area MEET2WIN will take place at the same time as the MATWIN International Board Participants will have the opportunity to exchange with the committee members oncology academic key opinion leaders and pharma industry international leaders Why should you participate To identify partners for a collaborative project To provide a particular knowledge or expertise To optimize your collaborations opportunities How can you participate Register online here and fill in

    Original URL path: http://www.matwin.org/meet2win_2016-p60.html (2016-02-11)
    Open archived version from archive

  • MATWIN - Call for proposal
    baromètre innovation thérapeutique 2012 MATWIN projects Contact Submit your PROJECT Latest news NEWS Oncology Business convention MEET2WIN 2016 MATWIN will organize in Bordeaux next May 12th and 13th 2016 the 2nd edition of Read more Subscribe to Coming next AGENDA Cancéropôle PACA annual congress June 30th July 1st 2016 The Cancéropôle PACA is organizing on June 30th and July 1st 2016 Read more Subscribe to Call for proposal MATWIN Deposit you letter of intent now Pourquoi candidater Vous souhaitez valoriser votre innovation en restant au coeur d un processus unique et bénéficier d une réelle plus value pédagogique Le label MATWIN sera garant de la qualité et de l attractivité de votre projet Qui peut candidater à MATWIN Vous travaillez pour une structure publique ou privée type start up et vous avez identifié une innovation en oncologie dont la PI est assurée Cette innovation présentant un fort potentiel de transfert relève du domaine du prédictif du diagnostic du thérapeutique ou du dispositif médical Comment candidater Contactez la plateforme MATWIN et déposez une lettre d intention avant le 30 juin 2015 Pour comprendre les objectifs et enjeux de MATWIN prenez connaissance du texte de l appel à candidatures et téléchargez les

    Original URL path: http://www.matwin.org/zoom_sur_/appel_a_candidatures_matwin-p46.html (2016-02-11)
    Open archived version from archive

  • MATWIN - Maturation & Accelerating Translation With Industry
    Contact Some fields contain errors Name Firstname Organisation Phone E mail Your message Please click this box if you wish to subscribe to our newsletter Mandatory fields In accordance with the provisions of French law no 78 17 dated January 6th 1978 relating to Information Technologies Files and Civil Liberties you have the right to access modify rectify or delete any personal data collected when you register on our website

    Original URL path: http://www.matwin.org/contact.html (2016-02-11)
    Open archived version from archive



  •